Ryan Kubota
Director of Investor Relations
Replay available
InnovAge Holding Corp. (NASDAQ: INNV) Q4 2025 earnings conference call, held 2025-09-09. Replay captured from the company's public earnings webcast.

Director of Investor Relations
Chief Executive Officer
Chief Financial Officer
President and Chief Operating Officer
Analyst, KeyBank Capital Markets
Analyst, William Blair
Analyst, Goldman Sachs
to the InnovAge fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 11 again. And now I'd like, as a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Ryan Kubota, Director of Investor Relations. Please go ahead, sir. Thank you, Operator. Good afternoon, and thank you all for joining the Innovate 2025 fourth quarter and fiscal year-end earnings call. With me today is Patrick Blair, CEO, and Ben Adams, CFO. Michael Scarborough, President and COO, will also be joining the Q&A portion of the call. Today, after the market closed, we issued an earnings press release containing detailed information on our 2025 fiscal fourth quarter and year-end results. You may access the release on the investor relations section of our company website, innovates.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, September 9th, 2025, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our earnings press release posted on our website. We may also make statements that are considered forward-looking, including those related to our 2026 fiscal year projections and guidance, future growth prospects and growth strategy, our clinical and operational value initiatives, Medicare and Medicaid rate increa...